Effects of Weight Loss and Reduced Hyperglycemia on the Kinetics of Insulin Secretion in Obese Non-Insulin Dependent Diabetes Mellitus*

Authors:
  • KPKenneth S. Polonsky
    Kenneth S. Polonsky
  • WBWilliam F. Beltz
    William F. Beltz
  • KGKay Griver
    Kay Griver
  • PWPenny Wallace
    Penny Wallace
  • GBGinger Brechtel
    Ginger Brechtel
  • RHRobert R. Henry
    Robert R. Henry

Abstract
Impairment in pancreatic production of insulin, a cardinal feature of noninsulin dependent diabetes mellitus (NIDDM), was quantified and the kinetics of insulin secretion characterized in six obese individuals with NIDDM before and after weight loss (18.0 .+-. 3.0 kg, mean .+-. SEM) using a validated mathematical model that employs C-peptide as a marker of the in vivo rate of insulin secretion. The metabolic clearance of C-peptide, assessed by decay analysis after bolus injection of biosynthetic human C-peptide, was not changed by weight loss (0.143 .+-. 0.009 L/min .cntdot. m2 vs. 0.137 .+-. 0.010 L/min .cntdot. m2). Kinetic parameters from each individual''s decay curve before and after weight loss were used to derive accurate rates of secretion during the basal (postabsorptive) state, an oral glucose tolerance test and two hyperglycemic clamps. Basal rates of insulin secretion declined 20 .+-. 5 pmol/min .cntdot. m2 (96 .+-. 15 to 76 .+-. 15 pmol/min .cntdot. m2, P < 0.05) concomitant with decreases of 6.9 .+-. 0.9 mmol/L in fasting serum glucose (13.7 .+-. 1.0 to 6.8 .+-. 0.7 mmol/L, P < 0.05), 60 .+-. 14 pmol/L in serum insulin (134 .+-. 30 to 74 .+-. 15 pmol/L, P < 0.05), and 0.15 .+-. 0.03 pmol/ml in plasma C-peptide (0.67 .+-. 0.11 to 0.52 .+-. 0.08 pmol/ml, P < 0.05) concentrations. As expected, weight loss resulted in improved glucose tolerance as measured by the glycemic profiles during the oral glucose tolerance test (P < 0.05 analysis of variance). The insulin secretory response before weight loss showed a markedly reduced ability to respond appropriately to an increase in the ambient serum glucose. After weight loss, the pancreatic response was more dynamic (P < 0.05, analysis of variance) and paralleled the moment-to-moment changes in glycemia. Insulin production above basal doubled (11.2 .+-. 3.2 to 24.5 .+-. 5.8 nmol/6h .cntdot. m2, P < 0.05) and peak rates of insulin secretion above basal tripled (55 .+-. 16 to 157 .+-. 32 pmol/min/m2, P < 0.05). To assess the .beta.-cell response to glucose per se and the changes associated with weight reduction, two hyperglycemic clamps were performed at steady state glucose levels in the range characteristic of individuals with severe NIDDM. At a fixed glycemia of 20 mmol/L, average rates of insulin secretion increased almost 2-fold with treatment (161 .+-. 41 to 277 .+-. 60 pmol/min .cntdot. m2, P < 0.05). At an increment of 6 mmol/L glucose above prevailing fasting glucose levels, the average rate of insulin secretion increased 53% (120 .+-. 21 to 183 .+-. 39 pmol/min .cntdot. m2, P < 0.05). Changes in the kinetics of insulin production were further characterized by comparing the prevailing level of glycemia (basal and two clamps) to the rate of insulin secretion. Before weight loss, there was no association between the steady state glucose levels and insulin secretion rates (r = 0.08). After weight loss, however, these parameters were strongly correlated (P = 0.58, P < 0.02) indicating improved responsivity of the .beta.-cell over the physiological range of serum glucose concentrations. In conclusion, weight loss in obese individuals with severe NIDDM results in: 1) no change in the metabolic clearance rate of C-peptide and 2) improvement of impaired .beta.-cell responsivity to both the absolute and incremental changes in glycemia such that the .beta.-cell response is more coordinated with changes in the prevailing serum glucose level.

This publication has 18 references indexed in Scilit: